Cartesian Therapeutics, Inc. (RNAC)
NASDAQ: RNAC · Real-Time Price · USD
7.87
+0.39 (5.21%)
At close: Mar 4, 2026, 4:00 PM EST
7.87
0.00 (0.00%)
After-hours: Mar 4, 2026, 4:10 PM EST
Cartesian Therapeutics Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Cartesian Therapeutics stock have an average target of 38.8, with a low estimate of 30 and a high estimate of 44. The average target predicts an increase of 393.01% from the current stock price of 7.87.
Analyst Consensus: Strong Buy
* Price targets were last updated on Jan 9, 2026.
Analyst Ratings
The average analyst rating for Cartesian Therapeutics stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Maintains $40 → $42 | Strong Buy | Maintains | $40 → $42 | +433.67% | Jan 9, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $40 → $30 | Strong Buy | Maintains | $40 → $30 | +281.19% | Nov 19, 2025 |
| BTIG | BTIG | Strong Buy Maintains $42 → $44 | Strong Buy | Maintains | $42 → $44 | +459.09% | Nov 14, 2025 |
| Wedbush | Wedbush | Buy Initiates $38 | Buy | Initiates | $38 | +382.85% | Jul 9, 2025 |
| Needham | Needham | Strong Buy Maintains $41 → $40 | Strong Buy | Maintains | $41 → $40 | +408.26% | May 8, 2025 |
Financial Forecast
Revenue This Year
2.01M
from 38.91M
Decreased by -94.84%
Revenue Next Year
600.27K
from 2.01M
Decreased by -70.08%
EPS This Year
-2.39
from -4.49
EPS Next Year
-3.44
from -2.39
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 2.4M | 2.0M | ||||
| Avg | 2.0M | 600,270 | ||||
| Low | 1.8M | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -93.8% | -0.5% | ||||
| Avg | -94.8% | -70.1% | ||||
| Low | -95.3% | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -2.33 | -2.75 | ||||
| Avg | -2.39 | -3.44 | ||||
| Low | -2.64 | -3.72 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.